Live GMAT classes with Target Test Prep start Nov 21 and Nov 22. First class free.

See classes
Target Test Prep · GMAT

Choose how you want to prepare

Learn live with an expert or move at your own pace. Every option includes the complete TTP study system.

Newsweek Readers’ Choice Awards 2026 winner: Target Test Prep, #1 Test Prep

Target Test Prep was voted #1 Best Test Prep in the 2026 Newsweek Readers’ Choice™ Awards.

★★★★★5.0563 reviews
GMATLiveTeachStarts Nov 22
Josh Braslow, Target Test Prep GMAT expert
LIVE ONLINE CLASSES

Get Ready for GMAT Test Day Faster with Live Online Classes

with Josh Braslow, 20+ years in test prep

Nov 22 · Josh Braslow
Sun · 9:30 AM to 12:30 PM ET
Included
40 hours of live online classes + 6 months of TTP OnDemand
  • Attend the first class for free
  • Every class is recorded, so you never fall behind
View classes & enroll
Limited seats availableTarget Test Prep
EALiveTeachOnDemandStart anytime
EXECUTIVE ASSESSMENT

Target Test Prep EA OnDemand

Self-paced EA prep. Study on your schedule.

EXECUTIVE ASSESSMENT

with

165+ EA score guarantee
$05-day trial no automatic billing
Schedule
Included
40 hours of live online classes plus six months of access to the complete TTP EA OnDemand course.
  • 165+ EA Score Guarantee
  • 4,100+ Quant, Verbal, and Integrated Reasoning practice questions
  • 400+ hours of in-depth video lessons
  • 3,000+ step-by-step video solutions
View EA class & enroll Start free 5-day trial
Limited cohort · enrollment openTrial includes full course accessTarget Test Prep
GMATOnDemandStart anytime
SELF-PACED MASTERCLASS

Target Test Prep GMAT OnDemand

Complete access from day one. Study on your schedule.

715+ score guarantee
$0to start then $127/mo
  • Personalized study plan and analytics
  • Thousands of lessons and practice questions

Argument Essay (Acid-Ease)

Expert replies
by havok » Sun May 01, 2011 11:01 am
The following appeared in an article in a consumer-products magazine:

"Two of today's best-selling brands of full-strength prescription medication for the relief of excess stomach acid, Acid-Ease and Pepticaid, are now available in milder nonprescription forms. Doctors have written 76 million more prescriptions for full-strength Acid-Ease than for full-strength Pepticaid. So people who need an effective but milder nonprescription medication for the relief of excess stomach acid should choose Acid-Ease."

This article essentially states that because Acid-Ease prescription medication is more commonly prescribed than Pepticaid, nonprescription strength Acid-Ease is a better choice than nonprescription Pepticaid. This argument fundamentally flawed. The author makes many assumptions that are not supported by the information provided; the author also makes sweeping statements about all people who need mild, effective medication for stomach acid relief.

Firstly, the author assumes that because doctors write more prescriptions for Acid-Ease than for Pepticaid, that Acid-Ease is a better product. It is not mentioned how long each product has been on the market. Pepticaid could be a new medicine that has come out recently whereas Acid-Ease has been available for a much longer time. This possible scenario would explain the discrepancy between the sales figures and nullify the argument that more sales means one product is better than the other.

Secondly, the author also assumes that the non-prescription versions of each medication are linear in terms of their effectiveness. Even if full-strength Acid-Ease is, in fact, a better product than full-strength Pepticaid; one cannot assume that nonprescription strength Acid-Ease is necessarily better than nonprescription strength Pepticaid.
Lastly, the author’s statement attempts to target anyone who requires medication for the relief of excess stomach acid. It is not stated whether or not the two medications have the same active ingredient or the same side effects. It is possible that the two medications use different ingredients to achieve the same results – much like antihistamines that use similar doses of different ingredients to help people cope with allergies – therefore the conclusion reached by the author is too encompassing given the actual facts provided. To make the statement more plausible, the author should have narrowed down the scope of the target demographic to people who already find full-strength Acid-Ease effective but too strong, and may prefer the mild non-prescription strength version of Acid-Ease.

The author has reached a conclusion that is not supported by evidence, but rather a loose association between non-descript sales figures and sweeping assumptions about the medications themselves. In order to make a stronger statement, the author should have either addressed the assumptions through evidence or narrowed down his or her demographic scope.
Join the discussion
Source: — GMAT Essays (AWA) |